Jade Biosciences, Inc. Common Stock JBIO Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $55.09M+24.6% | $88.44M+27.5% | $50.11M+61.0% | $220.94M+611% | $44.22M+385% | ||
| $256.21M+701% | $247.72M— | $148.8M+158% | —— | $31.99M-64.5% | ||
| $7.22M+521% | $12.66M+4,623% | $2.46M+30.9% | $2.04M-68.9% | $1.16M-70.2% | ||
| $318.52M+312% | $348.82M+401% | $201.36M+122% | $222.98M+101% | $77.37M-25.1% | ||
| $157K+7,750% | $170K— | $176K+1,157% | $147K-36.6% | $2K-99.2% | ||
| $690K+337% | $726K— | $740K+186% | $777K+25.1% | $158K-78.2% | ||
| $69K— | $69K-97.8% | $174K+115% | $60K-25.9% | —— | ||
| $319.43M+312% | $349.78M+380% | $202.45M+123% | $223.97M+101% | $77.53M-27.4% | ||
| $3.98M+5,667% | $2.15M+66.7% | $1.35M+48.7% | $7.59M+81.5% | $69K-97.9% | ||
| $22.29M+822% | $16.54M+37.9% | $22.36M+117% | $21.62M+27.0% | $2.42M-84.4% | ||
| $679K— | $724K— | $747K+822% | $792K+284% | —— | ||
| $808K+159% | $851K+104% | $867K+60.6% | $811K+19.1% | $312K-59.7% | ||
| $22.97M+824% | $17.26M-85.6% | $23.1M+121% | $22.41M+29.6% | $2.49M-84.4% | ||
| —— | —— | $2K— | $2K— | —— | ||
| $5K+66.7% | $5K+400% | $3K0.0% | $3K0.0% | $3K0.0% | ||
| $511.55M+64.7% | $506.77M+283,012% | $321.77M+4.5% | $318.86M+4.2% | $310.56M+11.9% | ||
| -$214.76M+8.8% | -$174.39M-271% | -$142.46M+37.4% | -$117.28M+44.5% | -$235.57M-26.2% | ||
| -$342K-784% | $129K— | $29K-87.1% | -$24K+71.1% | $50K+252% | ||
| $296.46M+455% | $332.52M+811% | $179.35M+1,164% | $201.56M+20,155,500% | -$83.51M-192% | ||
| $319.43M+312% | $349.78M+380% | $202.45M+123% | $223.97M+101% | $77.53M-27.4% | ||
| $69K— | $69K-97.8% | $174K+115% | $60K-25.9% | —— | ||
| $690K+337% | $726K— | $740K+186% | $777K+25.1% | $158K-78.2% | ||
| $690K+337% | $726K— | $740K+186% | $777K+25.1% | $158K-78.2% | ||
| $69K— | $69K-97.8% | $174K+115% | $60K-25.9% | —— | ||
| $256.21M+701% | $247.72M— | $148.8M+158% | —— | $31.99M-64.5% | ||
| $690K+337% | $726K— | $740K+186% | $777K+25.1% | $158K-78.2% | ||
| $69K— | $69K-97.8% | $174K+115% | $60K-25.9% | —— | ||
| $14.85M— | $9.42M+128% | $14.01M— | $8.09M— | —— | ||
| $794K— | $4.97M-9.7% | $2.05M— | $2.38M— | —— | ||
| $2.67M— | $0-100% | $4.95M— | $3.56M— | —— | ||
| —— | $0-100% | $0— | —— | —— | ||
| $808K+159% | $851K+104% | $867K+60.6% | $811K+19.1% | $312K-59.7% | ||
| $5K+66.7% | $5K+400% | $3K0.0% | $3K0.0% | $3K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Jade Biosciences, Inc. Common Stock's total assets?
- Jade Biosciences, Inc. Common Stock (JBIO) holds $319.4M in total assets, up 312.0% year over year.
- How much debt does Jade Biosciences, Inc. Common Stock have?
- Jade Biosciences, Inc. Common Stock carries $808.0K in total debt against $296.5M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Jade Biosciences, Inc. Common Stock have?
- Jade Biosciences, Inc. Common Stock holds $55.1M in cash and equivalents.
- Can Jade Biosciences, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 14.29 — current assets exceed current liabilities.
- Where does Jade Biosciences, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.